

## Special Issue

# Neutrophils in Immunity and Diseases

### Message from the Guest Editor

Neutrophils have been historically linked to antimicrobial functions in acute infection. Recent evidence, however, has engaged them in hitherto unsuspecting functions and so neutrophils are now valued as functionally versatile cells with important roles in chronic inflammation. In particular, shifts in neutrophil phenotype enables them to adapt their function in different inflammatory contexts, in which they exert their regulatory role on both innate and adaptive immune leukocytes. The multifaceted involvement of neutrophils in several inflammatory conditions makes them exciting targets for therapeutic intervention. Of course, numerous challenges and controversies in the field remain. Overall, I would like to encourage the researchers, involved in such research topics, to provide their data, thoughts and concerns in order to have a broader view of the current state of the specific research area. Thus, readers will enjoy reading innovative papers, while overall we will be helped to anticipate the future directions of neutrophil biology.

### Guest Editor

Dr. Akrivi Chrysanthopoulou

Department of Biological Applications & Technology, Faculty of Health Sciences, University of Ioannina, Ioannina, Greece

### Deadline for manuscript submissions

closed (31 October 2024)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/160335](https://mdpi.com/si/160335)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).